199 related articles for article (PubMed ID: 26451330)
1. Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity.
Xu Y; Hijazi Y; Wolf A; Wu B; Sun YN; Zhu M
CPT Pharmacometrics Syst Pharmacol; 2015 Sep; 4(9):507-15. PubMed ID: 26451330
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL-6 levels following administration of the T-cell bispecific engager glofitamab.
Djebli N; Parrott N; Jaminion F; O'Jeanson A; Guerini E; Carlile D
CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):396-409. PubMed ID: 38044486
[TBL] [Abstract][Full Text] [Related]
3. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Pharmacokinetic Modeling To Predict Drug-Biologic Interactions with Cytokine Modulators: Are These Relevant and Is Interleukin-6 Enough?
Chen KF; Jones HM; Gill KL
Drug Metab Dispos; 2022 Oct; 50(10):1322-1331. PubMed ID: 36100353
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma.
Hijazi Y; Klinger M; Kratzer A; Wu B; Baeuerle PA; Kufer P; Wolf A; Nagorsen D; Zhu M
Curr Clin Pharmacol; 2018; 13(1):55-64. PubMed ID: 29773068
[TBL] [Abstract][Full Text] [Related]
6. Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations.
Machavaram KK; Endo-Tsukude C; Terao K; Gill KL; Hatley OJ; Gardner I; Parrott N; Ducray PS
AAPS J; 2019 Mar; 21(3):42. PubMed ID: 30887238
[TBL] [Abstract][Full Text] [Related]
7. Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6.
Jiang X; Zhuang Y; Xu Z; Wang W; Zhou H
AAPS J; 2016 May; 18(3):767-76. PubMed ID: 26961818
[TBL] [Abstract][Full Text] [Related]
8. Suppression of cytochrome P450- and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes.
Monshouwer M; Witkamp RF; Nujmeijer SM; Van Amsterdam JG; Van Miert AS
Toxicol Appl Pharmacol; 1996 Apr; 137(2):237-44. PubMed ID: 8661349
[TBL] [Abstract][Full Text] [Related]
9. HepaRG cells as human-relevant in vitro model to study the effects of inflammatory stimuli on cytochrome P450 isoenzymes.
Rubin K; Janefeldt A; Andersson L; Berke Z; Grime K; Andersson TB
Drug Metab Dispos; 2015 Jan; 43(1):119-25. PubMed ID: 25371393
[TBL] [Abstract][Full Text] [Related]
10. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
11. A novel drug interaction between busulfan and blinatumomab.
Sweiss K; Quigley JG; Oh A; Lee J; Ye R; Rondelli D; Patel P
J Oncol Pharm Pract; 2019 Jan; 25(1):226-228. PubMed ID: 28857712
[TBL] [Abstract][Full Text] [Related]
12. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture.
Dickmann LJ; Patel SK; Rock DA; Wienkers LC; Slatter JG
Drug Metab Dispos; 2011 Aug; 39(8):1415-22. PubMed ID: 21555507
[TBL] [Abstract][Full Text] [Related]
13. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
Klinger M; Brandl C; Zugmaier G; Hijazi Y; Bargou RC; Topp MS; Gökbuget N; Neumann S; Goebeler M; Viardot A; Stelljes M; Brüggemann M; Hoelzer D; Degenhard E; Nagorsen D; Baeuerle PA; Wolf A; Kufer P
Blood; 2012 Jun; 119(26):6226-33. PubMed ID: 22592608
[TBL] [Abstract][Full Text] [Related]
14. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450-mediated herb-drug interaction (HDI) of Polygonum multiflorum Thunb. based on pharmacokinetic studies and in vitro inhibition assays.
Xing Y; Yu Q; Zhou L; Cai W; Zhang Y; Bi Y; Zhang Y; Fu Z; Han L
Phytomedicine; 2023 Apr; 112():154710. PubMed ID: 36805481
[TBL] [Abstract][Full Text] [Related]
16. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
Nordmark A; Andersson A; Baranczewski P; Wanag E; Ståhle L
Eur J Clin Pharmacol; 2014 Feb; 70(2):167-78. PubMed ID: 24186263
[TBL] [Abstract][Full Text] [Related]
17. Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models.
Yu Z; Lei Z; Yao X; Wang H; Zhang M; Hou Z; Li Y; Zhao Y; Li H; Liu D; Zhai Y
Front Pharmacol; 2022; 13():1065130. PubMed ID: 36582520
[TBL] [Abstract][Full Text] [Related]
18. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
19. Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans.
Jiang X; Chen X; Jaiprasart P; Carpenter TJ; Zhou R; Wang W
Eur J Pharm Sci; 2020 Apr; 146():105260. PubMed ID: 32058058
[TBL] [Abstract][Full Text] [Related]
20. Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam.
Perkins EJ; Posada M; Kellie Turner P; Chappell J; Ng WT; Twelves C
Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):355-367. PubMed ID: 29119333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
